4-Chloro-3-nitrobenzoic Acid | CAS:96-99-1

We serve 4-Chloro-3-nitrobenzoic Acid CAS:96-99-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Chloro-3-nitrobenzoic Acid

Chemical Name:4-Chloro-3-nitrobenzoic Acid
CAS.NO:96-99-1
Synonyms:4-Chloro-3-nitrobenzoic Acid
3-Nitro-4-chlorobenzoic acid
 
Physical and Chemical Properties:
Density 1.6±0.1 g/cm3
Boiling Point 371.6±27.0 °C at 760 mmHg
Melting Point 180-183 °C(lit.)
Molecular Formula C7H4ClNO4
Molecular Weight 201.564
Flash Point 178.5±23.7 °C
 
Specification:
Appearance:White to light yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Dabigatran Etexilate Mesylate(CAS:872728-81-9) and Dabigatran etexilate(CAS:211915-06-9).



Contact us for information like 4-Chloro-3-nitrobenzoic Acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Nitro-4-chlorobenzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Nitro-4-chlorobenzoic acid Use and application,3-Nitro-4-chlorobenzoic acid technical grade,usp/ep/jp grade.


Related News: In order to find answers to these questions, our staff in the development department set about conducting a series of experiments.3-Ethoxyacryloyl chloride manufacturer Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).2-(3'-Chloro[1,1'-biphenyl]-3-yl)-4,6-diphenyl-1,3,5-triazine supplier China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.5-Fluoro-1-pentanol vendor US citizens who’ve been in other parts of mainland China in the last 14 days will undergo screening at US ports of entry and up to 14 days of self-monitoring.Since inception in 2004, ICIG has acquired 15 businesses, all of which have origins in major global chemical or pharmaceutical corporations and are independently managed.